

Investigation Report on China Glipizide Market, 2010-2019

<https://marketpublishers.com/r/I1E3CC4109EEN.html>

Date: July 2015

Pages: 30

Price: US\$ 2,000.00 (Single User License)

ID: I1E3CC4109EEN

Abstracts

Description

According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.

As one of the earliest oral antidiabetic drugs, sulfonylurea is common to patients with insulin hyposecretion. By stimulating insulin secretion, sulfonylurea is able to reduce blood glucose. According to the length of action, sulfonylurea can be categorized into short-acting, medium-acting and long-acting preparations. And glibenclamide, glipizide, glimepiride and glipizide are the common drugs in the class of sulfonylurea.

As the first-line drug for type 2 diabetes, glipizide belongs to the second generation of sulfonylurea and it works by stimulating insulin secretion. Developed by Pfizer, glipizide was approved by FDA to enter the market in Apr. 1994. Glipizide in the Chinese market mainly comes from Pfizer (Trade Name: Glucotrol Common Name: Glipizide Controlled Release Tablets), Disha Pharmaceutical Group (Trade Name: Dishapian Common

Name: Glipizide Tablets) and Yangtze River Pharmaceutical Group (Trade Name: Qinsu Common Name: Glipizide Extended Release Tablets). Although quite a lot local enterprises produce gliclazide, they all took up a small market share.

According to CRI's market survey, in 2014, Pfizer (US) took up a market share of about 86% for sales value in China while other companies like Shandong Wanjie High-tech Co., Ltd, Yangtze River Pharmaceutical Group and Disha Pharmaceutical Group shared the rest market share. The annual sales value of glipizide stays at CNY 50-60 million during the period of 2005-2014.

The market size of glipizide is expected to stay at a certain level in the next few years in China.

Readers can get at least the following information through this report:

market size of glipizide in China

major manufacturers of glipizide for Chinese market and their market share

retail price of glipizide in Chinese market

market outlook of glipizide in China

The author suggests the following groups of people purchase this report:

manufacturers of anti-diabetic drugs

investors/ research institutions interested in Chinese medicine market

any interest in the medicine market, please contact CRI for customized survey service

Contents

1 RELATED CONCEPTS OF GLIPIZIDE

- 1.1 Indication
- 1.2 Sales Status in Global Market

2 MARKET PROFILE OF GLIPIZIDE IN CHINA

- 2.1 Patent Status
- 2.2 Major Manufacturers
- 2.3 Market Size

3 SURVEY ON SALES STATUS OF GLIPIZIDE IN CHINA, 2010-2014

- 3.1 Sales Value
 - 3.1.1 Overall Sales Value
 - 3.1.2 Sales Value by Regions
- 3.2 Sales Volume
 - 3.2.1 Overall Sales Volume
 - 3.2.2 Sales Volume by Regions

4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF GLIPIZIDE IN CHINA, 2010-2014

- 4.1 Market Share by Sales Value
- 4.2 Market Share by Sales Volume

5 SURVEY ON DOSAGE FORMS OF GLIPIZIDE IN CHINA, 2010-2014

- 5.1 Share of Different Dosage Forms by Sales Value
- 5.2 Share of Different Dosage Forms by Sales Volume

6 REFERENCE PRICE OF GLIPIZIDE IN CHINESE HOSPITALS IN 2014

- 6.1 Pfizer (US)
- 6.2 Shandong Wanjie High-tech Co., Ltd
- 6.3 Yangtze River Pharmaceutical Group
- 6.4 Disha Pharmaceutical Group

6.5 Hangzhou Conba Pharmaceutical Co., Ltd

6.6 Shanghai Sine Pharmaceutical Co., Ltd

7 MAJOR MANUFACTURERS OF GLIPIZIDE IN CHINESE MARKET, 2010-2014

7.1 Pfizer (US)

7.2 Shandong Wanjie High-tech Co., Ltd

7.3 Yangtze River Pharmaceutical Group

7.4 Disha Pharmaceutical Group

7.5 Hangzhou Conba Pharmaceutical Co., Ltd

8 MARKET OUTLOOK OF GLIPIZIDE IN CHINA, 2015-2019

8.1 Forecast of Market Size

8.2 Forecast of Competitive Landscape

TABLE OF SELECTED CHARTS

Chart Patent Registration Information of Glipizide in China

Chart Approval Status of Glipizide in China

Chart Sales Status of Glipizide in China, 2010-2014

Chart Sales Value of Glipizide in China, 2010-2014

Chart Sales Value of Glipizide by Regions in China, 2010-2014

Chart Sales Value of Glipizide Tablets in China, 2010-2014

Chart Sales Value of Glipizide Capsules in China, 2010-2014

Chart Market Share of Major Manufacturers of Glipizide for Sales Value in China, 2010-2014

Chart Sales Value and Market Share of Glipizide Made by Pfizer (US) in China, 2010-2014

Chart Sales Value and Market Share of Glipizide Made by Shandong Wanjie High-tech Co., Ltd in China, 2010-2014

Chart Sales Value and Market Share of Glipizide Made by Yangtze River Pharmaceutical Group in China, 2010-2014

Chart Sales Value and Market Share of Glipizide Made by Disha Pharmaceutical Group in China, 2010-2014

Chart Price of Glipizide Made by Pfizer (US) in Some Chinese Cities in 2014

Chart Price of Glipizide Made by Shandong Wanjie High-tech Co., Ltd in Some Chinese Cities in 2014

Chart Price of Glipizide Made by Pfizer (US) in Some Chinese Cities in 2014

Chart Price of Glipizide Made by Disha Pharmaceutical Group in Some Chinese Cities in 2014

Chart Price of Glipizide Made by Hangzhou Conba Pharmaceutical Co., Ltd in Some Chinese Cities in 2014

Chart Price of Glipizide Made by Shanghai Sine Pharmaceutical Co., Ltd in Some Chinese Cities in 2014

I would like to order

Product name: Investigation Report on China Glipizide Market, 2010-2019

Product link: <https://marketpublishers.com/r/l1E3CC4109EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l1E3CC4109EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970